These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 8853935)
1. Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations. Rensen PC; de Vrueh RL; van Berkel TJ Clin Pharmacokinet; 1996 Aug; 31(2):131-55. PubMed ID: 8853935 [TBL] [Abstract][Full Text] [Related]
2. Selective liver targeting of antivirals by recombinant chylomicrons--a new therapeutic approach to hepatitis B. Rensen PC; van Dijk MC; Havenaar EC; Bijsterbosch MK; Kruijt JK; van Berkel TJ Nat Med; 1995 Mar; 1(3):221-5. PubMed ID: 7585037 [TBL] [Abstract][Full Text] [Related]
3. Latest developments in the treatment of hepatitis B. Dandri M; Petersen J Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309 [TBL] [Abstract][Full Text] [Related]
4. Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients. Liao YP; Jiang JL; Zou WY; Xu DR; Li J World J Gastroenterol; 2015 Apr; 21(14):4284-92. PubMed ID: 25892880 [TBL] [Abstract][Full Text] [Related]
5. HepDirect prodrugs for targeting nucleotide-based antiviral drugs to the liver. Erion MD; Bullough DA; Lin CC; Hong Z Curr Opin Investig Drugs; 2006 Feb; 7(2):109-17. PubMed ID: 16499280 [TBL] [Abstract][Full Text] [Related]
6. [Famciclovir plus interferon in the treatment of a patient with chronic hepatitis B and severe liver failure]. Piqueras B; Salcedo M; Bañares R; García-Durán F; Baños E; de Diego A; Roldán P; Cos E; Clemente G Rev Esp Enferm Dig; 1997 Mar; 89(3):217-21. PubMed ID: 9198481 [TBL] [Abstract][Full Text] [Related]
7. Hepatitis B virus: old, new and future approaches to antiviral treatment. Karayiannis P J Antimicrob Chemother; 2003 Apr; 51(4):761-85. PubMed ID: 12654750 [TBL] [Abstract][Full Text] [Related]
8. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. McKenzie R; Fried MW; Sallie R; Conjeevaram H; Di Bisceglie AM; Park Y; Savarese B; Kleiner D; Tsokos M; Luciano C N Engl J Med; 1995 Oct; 333(17):1099-105. PubMed ID: 7565947 [TBL] [Abstract][Full Text] [Related]
9. Liver targeting of nucleoside analogues coupled to galactosyl terminating macromolecules: a new approach to the treatment of a chronic viral hepatitis. Fiume L; Verme G Ital J Gastroenterol Hepatol; 1997 Jun; 29(3):275-80. PubMed ID: 9646223 [TBL] [Abstract][Full Text] [Related]
10. Novel viral and host targets to cure hepatitis B. Ko C; Michler T; Protzer U Curr Opin Virol; 2017 Jun; 24():38-45. PubMed ID: 28433762 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial. Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701 [TBL] [Abstract][Full Text] [Related]
12. Liver targeting of adenine arabinoside monophosphate (ara-AMP) by coupling to lactosaminated human serum albumin. Fiume L; Busi C; Di Stefano G; Mattioli A; Torrani-Cerenzia M; Bonino F; Capra G; De Bernardi W; Ponzetto A; Lavezzo B Ital J Gastroenterol; 1995 May; 27(4):189-92. PubMed ID: 8520036 [TBL] [Abstract][Full Text] [Related]
13. Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection. Marinos G; Naoumov NV; Williams R Hepatology; 1996 Nov; 24(5):991-5. PubMed ID: 8903365 [TBL] [Abstract][Full Text] [Related]
14. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. Delaney WE; Locarnini S; Shaw T Antivir Chem Chemother; 2001 Jan; 12(1):1-35. PubMed ID: 11437320 [TBL] [Abstract][Full Text] [Related]
15. [Study on efficacy and safety of lamivudine and interferon-alpha in treatment of hepatitis B virus transgenic mice with pregnancy]. Li D; Yan YP; Xu DZ; Men K; Zhang JX; Lei XY Zhonghua Fu Chan Ke Za Zhi; 2005 May; 40(5):315-9. PubMed ID: 15938781 [TBL] [Abstract][Full Text] [Related]
16. Targeting of antiviral drugs by coupling with protein carriers. Fiume L; Busi C; Mattioli A FEBS Lett; 1983 Mar; 153(1):6-10. PubMed ID: 6186534 [TBL] [Abstract][Full Text] [Related]
17. The progress of antiviral therapy in patients with HBV-related liver failure. Zhou Q; Tang H Hepatogastroenterology; 2013; 60(128):1877-80. PubMed ID: 24719921 [TBL] [Abstract][Full Text] [Related]
18. Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues. Dusheiko G Liver Int; 2013 Feb; 33 Suppl 1():137-50. PubMed ID: 23286858 [TBL] [Abstract][Full Text] [Related]
19. Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C. Fabris P; Brown D; Tositti G; Bozzola L; Giordani MT; Bevilacqua P; de Lalla F; Webster GJ; Dusheiko G J Clin Virol; 2004 Mar; 29(3):160-6. PubMed ID: 14962784 [TBL] [Abstract][Full Text] [Related]
20. Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial. Xu Y; Wang X; Liu Z; Zhou C; Qi W; Jiao J; Yu F; Guo H; Zhao P; Wang J BMC Gastroenterol; 2017 Aug; 17(1):102. PubMed ID: 28854883 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]